RyosukeTsugitomi· @Rtsugitom · X·· 1 day agoScore70
Body · original
Although challenges remain in how best to identify MET alterations, this looks like a highly promising treatment option following progression on osimertinib!
#ESMO26
27 views · 0 likes · 0 reposts · 2 replies
②SAFFRON: Osimertinib + savolitinib vs. platinum-based chemotherapy in patients with EGFR-mutated, MET-overexpressed or MET-amplified NSCLC following progression on osimertinib在 X 查看被引用的帖子
Replies in this thread
- RyosukeTsugitomi@Rtsugitom
https://x.com/NEJM/status/2114380721066295632?s=20
- RyosukeTsugitomi@Rtsugitom
Are we heading back to the days when we were desperately chasing T790M through repeat biopsies..? But perhaps that's how it should be.
Source: RyosukeTsugitomi · x.com